Status:
COMPLETED
Retrospective Study on Caplacizumab-treated Pediatric Patients With Immune-mediated Thrombocytopenic Purpura (iTTP)
Lead Sponsor:
Sanofi
Conditions:
Immune-mediated Thrombocytopenic Purpura
Eligibility:
All Genders
Up to 18 years
Brief Summary
The purpose of this multi-country, retrospective data collection study (chart review) is to describe the effectiveness and safety of caplacizumab in pediatric patients with iTTP.
Detailed Description
Pediatric patients who received caplacizumab will be identified for enrollment in the chart review. The eligibility period starts on August 30, 2018 in the United Kingdom (UK) and France and February ...
Eligibility Criteria
Inclusion
- Patient's aged ≤18 years at start of caplacizumab treatment initiation
- Patient has a diagnosis of iTTP documented in the medical records
- Patient was treated with caplacizumab within the eligibility period
Exclusion
- Patient declined use of data for study (where local regulations require patient notification of planned study)
- Patient's medical chart is missing or not retrievable
Key Trial Info
Start Date :
June 8 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 28 2022
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT05263193
Start Date
June 8 2022
End Date
October 28 2022
Last Update
December 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis
Chilly-Mazarin, France, 91380